Here, we report that the combination of CBDCA and anti-PD-1 antibodies improves survival rates as neoadjuvant immunochemotherapy for secondary tumors after surgery in three murine TNBC models, and enhance tumor-infiltrating T cell functions by elevating CCL4 expression and increasing the number of CD103+ dendritic cells (DC) in the tumor microenvironment. The gene discussed is PDCD1; the disease is neoplasm.